NASDAQ · CURX
Healthcare · Biotechnology
$4.71
Down-$0.56 (-10.63%)
Updated Aug 24, 2026, 12:11 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CURX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CURX.
CURX research
Company profile and research snapshot.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
ChartMill · Feb 26, 2026
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
ChartMill · Feb 26, 2026
Let's dive into the action on the US markets on Thursday. Here are the most active stocks that are driving the market today.
ChartMill · Feb 26, 2026
Unusual volume stocks in Thursday's session
ChartMill · Feb 26, 2026
Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CURX.
No results
No recent SID articles mention CURX.
